520500 恒生创新药ETF华泰柏瑞
已收盘 07-24 15:00:00
资讯
新帖
简况
7款国产FIC新药斩获CPIC重磅大奖！支持T+0交易的恒生创新药ETF华泰柏瑞（520500）年内份额增长近90%
新浪基金 · 07-24 14:58
7款国产FIC新药斩获CPIC重磅大奖！支持T+0交易的恒生创新药ETF华泰柏瑞（520500）年内份额增长近90%
跨国药企阿斯利康、礼来百亿级交易中国创新药！恒生创新药ETF华泰柏瑞(520500)T+0助力把握低估值创新药机遇
新浪基金 · 07-22 13:20
跨国药企阿斯利康、礼来百亿级交易中国创新药！恒生创新药ETF华泰柏瑞(520500)T+0助力把握低估值创新药机遇
出海爆发+投融资回暖+业绩预增！恒生创新药ETF华泰柏瑞（520500）T+0助力把握低估值创新药反弹机遇
新浪基金 · 07-21
出海爆发+投融资回暖+业绩预增！恒生创新药ETF华泰柏瑞（520500）T+0助力把握低估值创新药反弹机遇
【ETF动向】7月16日恒生创新药ETF华泰柏瑞基金跌1.7%，份额增加1.94亿份
证券之星 · 07-17
【ETF动向】7月16日恒生创新药ETF华泰柏瑞基金跌1.7%，份额增加1.94亿份
产业价值加速释放！恒生创新药ETF华泰柏瑞（520500）单日成交额超46亿元、创历史新高！
新浪基金 · 07-16
产业价值加速释放！恒生创新药ETF华泰柏瑞（520500）单日成交额超46亿元、创历史新高！
国家基本药物目录首次纳入创新药！"出海+政策"双重催化、恒生创新药ETF华泰柏瑞(520500)近3个月份额增超50%
新浪基金 · 07-10
国家基本药物目录首次纳入创新药！"出海+政策"双重催化、恒生创新药ETF华泰柏瑞(520500)近3个月份额增超50%
全球TOP10交易中国独占8席！恒生创新药ETF华泰柏瑞（520500）T+0助力把握创新药反弹机遇
新浪基金 · 07-08
全球TOP10交易中国独占8席！恒生创新药ETF华泰柏瑞（520500）T+0助力把握创新药反弹机遇
【ETF动向】7月6日恒生创新药ETF华泰柏瑞基金涨2.51%，份额增加1亿份
证券之星 · 07-07
【ETF动向】7月6日恒生创新药ETF华泰柏瑞基金涨2.51%，份额增加1亿份
千亿出海潮释放高景气信号！借道恒生创新药ETF华泰柏瑞、创新药ETF华泰柏瑞助力把握创新药商业化兑现主线
新浪基金 · 07-06
千亿出海潮释放高景气信号！借道恒生创新药ETF华泰柏瑞、创新药ETF华泰柏瑞助力把握创新药商业化兑现主线
创新药企携手阿斯利康再达重磅国际合作！全市场仅有的恒生创新药ETF华泰柏瑞连续9个交易日成交额突破10亿
新浪基金 · 07-02
创新药企携手阿斯利康再达重磅国际合作！全市场仅有的恒生创新药ETF华泰柏瑞连续9个交易日成交额突破10亿
医保、商保、集采三重优化共振创新药板块！借道恒生创新药ETF华泰柏瑞（520500）助力布局板块修复机遇
新浪基金 · 07-01
医保、商保、集采三重优化共振创新药板块！借道恒生创新药ETF华泰柏瑞（520500）助力布局板块修复机遇
ETF日报(06.29)丨医保目录利好提振市场信心，创新药全线爆发 半导体设备ETF异动走强
智通财经 · 06-29
ETF日报(06.29)丨医保目录利好提振市场信心，创新药全线爆发 半导体设备ETF异动走强
创新药产业链回购增持密集，恒生创新药ETF华泰柏瑞（520500）最新单日成交额放量突破20亿元！
新浪基金 · 06-24
创新药产业链回购增持密集，恒生创新药ETF华泰柏瑞（520500）最新单日成交额放量突破20亿元！
152亿美元重磅BD交易再破历史纪录！恒生创新药ETF华泰柏瑞（520500）连续8个交易日获资金净流入
新浪基金 · 05-20
152亿美元重磅BD交易再破历史纪录！恒生创新药ETF华泰柏瑞（520500）连续8个交易日获资金净流入
94项中国药企研究入选2026年ASCO年会，恒生创新药ETF华泰柏瑞（520500）基金份额连续创下历史新高！
新浪基金 · 05-19
94项中国药企研究入选2026年ASCO年会，恒生创新药ETF华泰柏瑞（520500）基金份额连续创下历史新高！
【ETF动向】5月15日恒生创新药ETF华泰柏瑞基金跌2.07%，份额增加1.13亿份
证券之星 · 05-16
【ETF动向】5月15日恒生创新药ETF华泰柏瑞基金跌2.07%，份额增加1.13亿份
【ETF动向】5月13日恒生创新药ETF华泰柏瑞基金跌2.5%，份额增加7850万份
证券之星 · 05-14
【ETF动向】5月13日恒生创新药ETF华泰柏瑞基金跌2.5%，份额增加7850万份
【ETF动向】4月23日恒生创新药ETF华泰柏瑞基金跌5.39%，份额增加1.08亿份
证券之星 · 04-24
【ETF动向】4月23日恒生创新药ETF华泰柏瑞基金跌5.39%，份额增加1.08亿份
BD放量+盈利拐点+数据催化，恒生创新药ETF华泰柏瑞、恒生生物科技ETF华泰柏瑞助力布局创新药高景气赛道
新浪基金 · 04-08
BD放量+盈利拐点+数据催化，恒生创新药ETF华泰柏瑞、恒生生物科技ETF华泰柏瑞助力布局创新药高景气赛道
恒生创新药ETF领涨全市场！关注港股科技底仓工具
同壁财经 · 03-05
恒生创新药ETF领涨全市场！关注港股科技底仓工具
暂无数据
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"520500","market":"SH","secType":"STK","nameCN":"恒生创新药ETF华泰柏瑞","latestPrice":1.399,"timestamp":1784876400000,"preClose":1.431,"halted":0,"volume":1285796890,"delay":0,"changeRate":-0.0224,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.032,"latestTime":"07-24 15:00:00","open":1.417,"high":1.452,"low":1.398,"amount":1833000000,"amplitude":0.0377,"askPrice":1.4,"askSize":26594,"bidPrice":1.399,"bidSize":7665,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":5,"adr":0,"adjPreClose":1.431,"symbolType":"fund","openAndCloseTimeList":[[1784856600000,1784863800000],[1784869200000,1784876400000]],"highLimit":1.574,"lowLimit":1.288,"ibTradeSell":false,"ibTradeBuySell":false,"isCdr":false,"pbRate":0,"committee":0.112421,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/520500/tweets","defaultTab":"tweets","newsList":[{"id":"2653019917","title":"7款国产FIC新药斩获CPIC重磅大奖！支持T+0交易的恒生创新药ETF华泰柏瑞（520500）年内份额增长近90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653019917","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653019917?lang=zh_cn&edition=full","pubTime":"2026-07-24 14:58","pubTimestamp":1784876280,"startTime":"0","endTime":"0","summary":"近期国内创新药全球化进程持续提速，多项重磅BD授权合作密集落地。医药魔方统计显示，截至7月21日，年内创新药License-out出海交易合计140笔，交易总额1099亿美元、首付款59亿美元，两项指标分别完成2025全年规模的79%、82%，海外商业化拓展节奏显著加快。作为当前全市场仅有的跟踪恒生创新药指数的ETF，恒生创新药ETF华泰柏瑞在近一个月的23个交易日中有19日单日成交金额突破20亿元，区间日均成交额达到26.51亿元，大幅高于年初以来11.41亿元的均值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-24/doc-iniiwvki4893035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653739398","title":"跨国药企阿斯利康、礼来百亿级交易中国创新药！恒生创新药ETF华泰柏瑞(520500)T+0助力把握低估值创新药机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2653739398","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653739398?lang=zh_cn&edition=full","pubTime":"2026-07-22 13:20","pubTimestamp":1784697600,"startTime":"0","endTime":"0","summary":"2026年以来，中国创新药BD出海呈现“量质双跃升”态势，交易模式从“单品授权”加速迈向“平台级合作”。国内药企与阿斯利康、礼来等跨国药企的百亿级交易密集落地，折射出全球头部跨国药企对中国研发体系认可度的系统性提升。2025年全年中国创新药BD交易总金额达1357亿美元，同比激增159%；2026年上半年License-out总金额已逼近997亿美元，相当于2025全年的73%、2024全年的1.9倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-22/doc-iniisawe8840431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653269226","title":"出海爆发+投融资回暖+业绩预增！恒生创新药ETF华泰柏瑞（520500）T+0助力把握低估值创新药反弹机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2653269226","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653269226?lang=zh_cn&edition=full","pubTime":"2026-07-21 13:43","pubTimestamp":1784612580,"startTime":"0","endTime":"0","summary":"近期，前期涨幅较大的科技板块迎来明显回调，市场波动有所放大。与之相对，创新药板块自上一轮调整后，估值仍处于历史低位区间——截至2026年7月20日，恒生创新药指数最新市盈率为43.70倍，处于近五年31.96%的分位水平。随着创新药BD出海、投融资回暖、前沿突破、头部药企释放盈利信号和密集回购等多重利好因素共振，该板块自2026年6月底以来逐步走出反弹行情，相关ETF交投活跃。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-21/doc-iniipxxh8087536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500","06978","159992","BK1161","BK1574","MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652420117","title":"【ETF动向】7月16日恒生创新药ETF华泰柏瑞基金跌1.7%，份额增加1.94亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2652420117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652420117?lang=zh_cn&edition=full","pubTime":"2026-07-17 06:31","pubTimestamp":1784241092,"startTime":"0","endTime":"0","summary":"证券之星消息，7月16日，恒生创新药ETF华泰柏瑞基金（520500）跌1.7%，成交额44.9亿元。当日份额增加了1.94亿份，最新份额为24.26亿份，近20个交易日份额增加4.59亿份。当日资金净流入2.7亿元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为35.4亿元。恒生创新药ETF华泰柏瑞基金跟踪标的为恒生创新药指数，成立（2024-12-16）以来超额回报为-3.11%，近一个月超额回报为0.18%，管理人为华泰柏瑞基金公司，基金经理为陈柯含。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700004909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651490033","title":"产业价值加速释放！恒生创新药ETF华泰柏瑞（520500）单日成交额超46亿元、创历史新高！","url":"https://stock-news.laohu8.com/highlight/detail?id=2651490033","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651490033?lang=zh_cn&edition=full","pubTime":"2026-07-16 11:12","pubTimestamp":1784171520,"startTime":"0","endTime":"0","summary":"近期在市场整体震荡盘整的背景下，创新药板块受多重因素催化逆势抢眼。亮眼表现也让创新药板块受到了市场资金的高度关注，恒生创新药ETF华泰柏瑞7月15日成交额达46.74亿元，刷新上市以来新高，同时近一周产品日均成交额达32.31亿元，交投持续活跃。近三个交易日恒生创新药ETF华泰柏瑞合计吸金2.13亿元，助推产品最新份额、规模分别达22.32亿份、32.7亿元，双双创下历史新高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-16/doc-inihyiym7986387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650909442","title":"国家基本药物目录首次纳入创新药！\"出海+政策\"双重催化、恒生创新药ETF华泰柏瑞(520500)近3个月份额增超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650909442","media":"新浪基金","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650909442?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:53","pubTimestamp":1783655580,"startTime":"0","endTime":"0","summary":"近日，创新药板块迎来多重催化，政策利好、出海加速共振下，港股创新药板块受到市场资金关注，恒生创新药ETF华泰柏瑞等优质场内工具交投情绪持续活跃。数据显示，其7月9日成交额达26.84亿元，7月以来日均成交额为25.49亿元，较上半年的8.81亿元日均成交水平显著抬升。资金也在加快布局步伐，恒生创新药ETF华泰柏瑞7月9日最近份额达21.09亿份，近三个月份额大增52.16%。本次更新首次将创新药纳入基药遴选调整范围，新纳入4款国产一类创新药。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-10/doc-inihhvke3936656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500","159992","MEDX","06978","BK1161","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649570849","title":"全球TOP10交易中国独占8席！恒生创新药ETF华泰柏瑞（520500）T+0助力把握创新药反弹机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2649570849","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649570849?lang=zh_cn&edition=full","pubTime":"2026-07-08 13:07","pubTimestamp":1783487220,"startTime":"0","endTime":"0","summary":"近期创新药产业多重积极因素共振，自2026年6月底以来板块迎来反弹。出海大单品的全球临床与审批节点逐步明朗，细胞治疗、AI制药等前沿领域持续突破，头部药企盈利信号趋于明确，叠加密集回购等积极因素，市场情绪明显回暖，相关ETF交投活跃。 目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞已连续4个交易日单日成交额突破20亿元，7月以来日均成交额高达25.13亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-08/doc-inihaieh4885016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500","06978","159992","BK1161","BK1574","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649674022","title":"【ETF动向】7月6日恒生创新药ETF华泰柏瑞基金涨2.51%，份额增加1亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2649674022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649674022?lang=zh_cn&edition=full","pubTime":"2026-07-07 06:31","pubTimestamp":1783377105,"startTime":"0","endTime":"0","summary":"证券之星消息，7月6日，恒生创新药ETF华泰柏瑞基金（520500）涨2.51%，成交额35.78亿元。当日份额增加了1亿份，最新份额为20.88亿份，近20个交易日份额增加8450万份。当日资金净流入2.29亿元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为29.98亿元。恒生创新药ETF华泰柏瑞基金跟踪标的为恒生创新药指数，成立（2024-12-16）以来超额回报为-3.52%，近一个月超额回报为-0.19%，管理人为华泰柏瑞基金公司，基金经理为陈柯含。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700004389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649364380","title":"千亿出海潮释放高景气信号！借道恒生创新药ETF华泰柏瑞、创新药ETF华泰柏瑞助力把握创新药商业化兑现主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2649364380","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649364380?lang=zh_cn&edition=full","pubTime":"2026-07-06 12:47","pubTimestamp":1783313220,"startTime":"0","endTime":"0","summary":"千亿出海潮释放创新药板块高景气信号！借道恒生创新药ETF华泰柏瑞、创新药ETF华泰柏瑞助力把握创新药“商业化兑现”主线。 目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞已连续2个交易日单日成交额突破20亿元，相较2026年以来9.15亿元的日均成交水平显著放量；另一人气产品——创新药ETF华泰柏瑞热度同样较高，已连续5个交易日获资金增持，仅上周五便获2.08亿份净申购，最新份额达7.95亿份，创历史新高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-06/doc-inifvuye8626767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500","BK1161","IBBQ","MEDX","159992","517120","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648579477","title":"创新药企携手阿斯利康再达重磅国际合作！全市场仅有的恒生创新药ETF华泰柏瑞连续9个交易日成交额突破10亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2648579477","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648579477?lang=zh_cn&edition=full","pubTime":"2026-07-02 13:17","pubTimestamp":1782969420,"startTime":"0","endTime":"0","summary":"某港股龙头药企发布公告，旗下子公司与阿斯利康达成战略合作，双方将携手开展新型靶免联合疗法用于非小细胞肺癌的临床试验，这一合作再度引发市场对国产创新药板块的关注。 目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞交投热度居高不下，产品已连续9个交易日单日成交额突破10亿元，本周一更是达27.64亿元，创下今年4月3日之后阶段新高，最新规模24.48亿元，场内流动性表现较亮眼。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-02/doc-inifkuqa2716838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443895.HKD","LU2237443382.USD","520500","BK4588","BK1161","LU2236285917.USD","LU2237443622.USD","LU0058720904.USD","LU2237443465.HKD","LU0289739699.SGD","BK1574","LU0889565916.HKD","LU0432979614.USD","AZNH","LU2468319806.SGD","LU0128525929.USD","IE00B3T34201.USD","LU2417539215.USD","LU0708994859.HKD","BK4007","LU2089984988.USD","LU1267930573.SGD","06978","LU2456880835.USD","BK4585","LU0109394709.USD","BK4568","LU0029864427.USD","LU0320765992.SGD","LU2237443978.SGD","159992","AZN","LU2462157665.USD","LU2237443549.SGD","LU1829250122.USD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648559040","title":"医保、商保、集采三重优化共振创新药板块！借道恒生创新药ETF华泰柏瑞（520500）助力布局板块修复机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2648559040","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648559040?lang=zh_cn&edition=full","pubTime":"2026-07-01 14:54","pubTimestamp":1782888840,"startTime":"0","endTime":"0","summary":"伴随医保目录初审结果的正式落地，“医保+商保”双目录谈判正式步入实操阶段，创新药行业正迎来政策红利集中释放周期。医保准入机制变革、商保衔接打通、集采规则优化三项制度协同推进，有效提振板块盘面活跃度。受此提振，目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞交易热度同步走高，截至今日早盘收盘，半日成交额已突破10.8亿元，达昨日全天成交额的64%，流动性优势较突出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-01/doc-inifhrqy6366719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500","06978","159992","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324093","title":"ETF日报(06.29)丨医保目录利好提振市场信心，创新药全线爆发 半导体设备ETF异动走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324093","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647324093?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:35","pubTimestamp":1782722103,"startTime":"0","endTime":"0","summary":"医保目录利好提振市场信心，创新药板块今日全线爆发；半导体硅片行业涨价信号密集释放，相关半导体设备ETF异动走强。截至收盘，创新药ETF华泰柏瑞涨9.43%，报0.673元；创新药ETF广发涨8.87%，报0.614元；恒生创新药ETF华泰柏瑞涨8.76%，报1.279元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0061475181.USD","BK4588","LU0787776722.HKD","LU2471134796.USD","IE00BK4W5L77.USD","LU2471134879.HKD","82800","LU2168563687.JPY","LU2168564495.EUR","LU1861220033.SGD","LU1868836914.USD","MUD","02800","LU0642271901.SGD","LU0889566641.SGD","03419","IE00B19Z3B42.SGD","LU0203347892.USD","588170","BK4533","520500","LU0859254822.USD","BK4543","LU0792757196.USD","LU0157215616.USD","LU2250418816.HKD","LU0238689110.USD","LU2458330243.SGD","IE00B5949003.HKD","517120","LU1803068979.SGD","IE0009356076.USD","LU0719512351.SGD","LU1323610961.USD","BK4554","MULL","LU0082616367.USD","IE00BKDWB100.SGD","IE0002270589.USD","BK4532","07747","LU2168564065.EUR","07709","03037","BK4579","LU0081259029.USD","LU0056508442.USD","SG9999001424.SGD","LU2750360641.GBP","LU2089985449.USD","LU1868837300.USD","LU2931357623.SGD","LU2360107168.USD","LU2357627491.SGD","BK4512","IE00B1XK9C88.USD","LU0889565833.HKD","515120","LU2360106780.USD","09115","IE00B7SZLL34.SGD","BK4553","07300","LU2168564222.USD","LU1861215975.USD","BK1610","LU2211815571.USD","IE00BK4W5M84.HKD","LU1852331112.SGD","BK4566","LU2750360997.AUD","BK4575","LU1914381329.SGD","LU2102340556.USD","03115","LU0127658192.USD","IE00BWXC8680.SGD","LU0096364046.USD","LU2458330169.SGD","BK4585","HSI","BK4605","LU2168564149.EUR","LU1366333091.USD","LU0683600562.USD","LU0203345920.USD","588710","LU0154236417.USD","LU2471134523.USD","LU0109392836.USD","IE000M9KFDE8.USD","LU0274383776.USD","BK4141","GB00BDT5M118.USD","LU1316542783.SGD","07500","IE0034235303.USD","LU1868837136.USD","LU1267930813.SGD","MU","LU2543165471.USD","159516","IE00B19Z3581.USD","LU2471134952.CNY","LU2286300806.USD","MUU","BK4527","LU2054465674.USD","83115","07200","LU2290526834.HKD","LU1868836757.USD","LU2048586759.USD","LU1868836591.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645862117","title":"创新药产业链回购增持密集，恒生创新药ETF华泰柏瑞（520500）最新单日成交额放量突破20亿元！","url":"https://stock-news.laohu8.com/highlight/detail?id=2645862117","media":"新浪基金","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645862117?lang=zh_cn&edition=full","pubTime":"2026-06-24 14:12","pubTimestamp":1782281520,"startTime":"0","endTime":"0","summary":"创新药板块自年内高点以来经历较充分调整，估值与机构持仓均处于相对低位。而随着前期压制市场的BD出海政策传言逐步证伪，叠加多家药企密集回购、7-8月中报业绩窗口临近，创新药赛道关注度正在升温。Wind及交易所数据显示，当前全市场仅有的跟踪恒生创新药指数的ETF产品——恒生创新药ETF华泰柏瑞最新规模突破24.37亿元，份额攀升至20.37亿份、创下历史新高。该ETF近3个交易日成交额呈放量态势、累计吸金超8200万，昨日单日成交额突破20亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-06-24/doc-inientty6298689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","520500","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636152648","title":"152亿美元重磅BD交易再破历史纪录！恒生创新药ETF华泰柏瑞（520500）连续8个交易日获资金净流入","url":"https://stock-news.laohu8.com/highlight/detail?id=2636152648","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636152648?lang=zh_cn&edition=full","pubTime":"2026-05-20 14:39","pubTimestamp":1779259140,"startTime":"0","endTime":"0","summary":"近期BD出海交易再迎重磅大单，叠加学术会议临近召开、财报彰显盈利拐点、政策暖风劲吹、BD出海持续提速，创新药赛道进入密集催化期，相关ETF受资金青睐。 中国创新药近期迎来重磅BD交易，金额再创历史新高！该协议潜在交易总金额可达约152亿美元、创中国BD历史之最，包含里程碑付款及销售分成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-05-20/doc-inhypnum1753549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636821508","title":"94项中国药企研究入选2026年ASCO年会，恒生创新药ETF华泰柏瑞（520500）基金份额连续创下历史新高！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636821508","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636821508?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:33","pubTimestamp":1779168780,"startTime":"0","endTime":"0","summary":"近期，创新药板块迎来多重催化：学术会议数据密集、财报彰显盈利拐点、政策暖风劲吹、BD出海持续提速。今日早盘相关ETF交投活跃。2026年ASCO年会将于5月底在芝加哥举行，本届大会中国创新药企业的表现呈现鲜明的“质量驱动”特征。据统计，2026年共34项中国研究入选ASCO口头汇报。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-05-19/doc-inhymcpk3304148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635055632","title":"【ETF动向】5月15日恒生创新药ETF华泰柏瑞基金跌2.07%，份额增加1.13亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2635055632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635055632?lang=zh_cn&edition=full","pubTime":"2026-05-16 06:32","pubTimestamp":1778884347,"startTime":"0","endTime":"0","summary":"证券之星消息，5月15日，恒生创新药ETF华泰柏瑞基金（520500）跌2.07%，成交额8.26亿元。当日份额增加了1.13亿份，最新份额为18.89亿份，近20个交易日份额增加5.04亿份。当日资金净流入1.07亿元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为27.18亿元。恒生创新药ETF华泰柏瑞基金跟踪标的为恒生创新药指数，成立（2024-12-16）以来超额回报为-3.27%，近一个月超额回报为0.31%，管理人为华泰柏瑞基金公司，基金经理为陈柯含。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051600005979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635852754","title":"【ETF动向】5月13日恒生创新药ETF华泰柏瑞基金跌2.5%，份额增加7850万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2635852754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635852754?lang=zh_cn&edition=full","pubTime":"2026-05-14 06:31","pubTimestamp":1778711510,"startTime":"0","endTime":"0","summary":"证券之星消息，5月13日，恒生创新药ETF华泰柏瑞基金（520500）跌2.5%，成交额7.37亿元。当日份额增加了7850万份，最新份额为17.22亿份，近20个交易日份额增加3.36亿份。当日资金净流入6376.21万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为25.78亿元。恒生创新药ETF华泰柏瑞基金跟踪标的为恒生创新药指数，成立（2024-12-16）以来超额回报为-3.44%，近一个月超额回报为0.22%，管理人为华泰柏瑞基金公司，基金经理为陈柯含。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400005659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629986199","title":"【ETF动向】4月23日恒生创新药ETF华泰柏瑞基金跌5.39%，份额增加1.08亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2629986199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629986199?lang=zh_cn&edition=full","pubTime":"2026-04-24 06:32","pubTimestamp":1776983528,"startTime":"0","endTime":"0","summary":"证券之星消息，4月23日，恒生创新药ETF华泰柏瑞基金（520500）跌5.39%，成交额11.12亿元。当日份额增加了1.08亿份，最新份额为15.55亿份，近20个交易日份额增加1.64亿份。当日资金净流入4086.3万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为24.69亿元。恒生创新药ETF华泰柏瑞基金跟踪标的为恒生创新药指数，成立（2024-12-16）以来超额回报为-4.12%，近一个月超额回报为-0.22%，管理人为华泰柏瑞基金公司，基金经理为陈柯含。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400020401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625999604","title":"BD放量+盈利拐点+数据催化，恒生创新药ETF华泰柏瑞、恒生生物科技ETF华泰柏瑞助力布局创新药高景气赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2625999604","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625999604?lang=zh_cn&edition=full","pubTime":"2026-04-08 11:27","pubTimestamp":1775618820,"startTime":"0","endTime":"0","summary":"2026年以来，中国创新药产业迎来多重利好共振：对外授权交易金额超预期增长，头部企业盈利拐点确立，近期国际学术大会更将密集催化管线数据。同时全球生物医药投融资明确复苏，带动CXO需求向好。当前地缘风险反复，生物科技板块经半年回调后估值处于合理区间，景气度持续上行、配置价值受青睐。 恒生生物科技ETF华泰柏瑞高度聚焦创新药与CXO两大核心赛道、累计权重达90%，兼顾纳入AI+医疗等前沿领域标的。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-04-08/doc-inhtucsa2855318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500","BK1161","159992","06978","513930","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617744591","title":"恒生创新药ETF领涨全市场！关注港股科技底仓工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2617744591","media":"同壁财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617744591?lang=zh_cn&edition=full","pubTime":"2026-03-05 11:03","pubTimestamp":1772679819,"startTime":"0","endTime":"0","summary":"ETF方面，恒生创新药ETF\\港股创新药ETF涨幅在A股上市的所有1000只ETF中位于领先地位；覆盖创新药龙头的港股通科技ETF盘中涨幅也超恒生科技ETF。相较恒生科技，多纳入了盈利预期强劲的创新药板块，在互联网、消费电子、新能源车等其他子板块面临一定盈利压力的当下，港股通科技ETF行业由于纳入创新药，分布更均衡，或为更优的港股科技底仓工具配置选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305112229a6a4b72e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305112229a6a4b72e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSI","520500","BK4585","159101","VXUS","VT","HSTECH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784914766977,"stockEarnings":[{"period":"1week","weight":0.0355},{"period":"1month","weight":0.1514},{"period":"3month","weight":-0.1229},{"period":"6month","weight":-0.147},{"period":"1year","weight":-0.2602},{"period":"ytd","weight":-0.088}],"compareEarnings":[{"period":"1week","weight":0.0133},{"period":"1month","weight":-0.0722},{"period":"3month","weight":-0.0651},{"period":"6month","weight":-0.0778},{"period":"1year","weight":0.0578},{"period":"ytd","weight":-0.039}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒生创新药ETF华泰柏瑞(520500)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒生创新药ETF华泰柏瑞(520500)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒生创新药ETF华泰柏瑞,520500,恒生创新药ETF华泰柏瑞股票,恒生创新药ETF华泰柏瑞股票老虎,恒生创新药ETF华泰柏瑞股票老虎国际,恒生创新药ETF华泰柏瑞行情,恒生创新药ETF华泰柏瑞股票行情,恒生创新药ETF华泰柏瑞股价,恒生创新药ETF华泰柏瑞股市,恒生创新药ETF华泰柏瑞股票价格,恒生创新药ETF华泰柏瑞股票交易,恒生创新药ETF华泰柏瑞股票购买,恒生创新药ETF华泰柏瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒生创新药ETF华泰柏瑞(520500)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒生创新药ETF华泰柏瑞(520500)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}